{"id":"high-dose-rosuvastatin","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"2-4","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. By reducing hepatic cholesterol production, the drug increases LDL receptor expression on hepatocytes, enhancing clearance of LDL cholesterol from the bloodstream. High-dose rosuvastatin provides more potent LDL-lowering effects compared to standard doses, reducing cardiovascular risk in patients with hypercholesterolemia and established cardiovascular disease.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:14.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of LDL cholesterol in patients at high cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":"Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction","enrollment":150},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT06782243","phase":"NA","title":"Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-20","conditions":"Acute Coronary Syndrome","enrollment":190},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT04499859","phase":"PHASE4","title":"Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI","status":"RECRUITING","sponsor":"Kiyuk Chang, MD,PhD","startDate":"2020-10-01","conditions":"Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity","enrollment":3548},{"nctId":"NCT03169985","phase":"PHASE4","title":"Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2017-07-12","conditions":"Coronary Artery Disease","enrollment":280},{"nctId":"NCT06186037","phase":"PHASE4","title":"Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Saint Vincent's Hospital, Korea","startDate":"2024-02-01","conditions":"Coronary Artery Disease, Dyslipidemias, Primary Prevention","enrollment":6356},{"nctId":"NCT07001787","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-06","conditions":"Dyslipidemia","enrollment":88},{"nctId":"NCT06231966","phase":"NA","title":"Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-04-22","conditions":"Peripheral Artery Disease, Polyvascular Disease","enrollment":2462},{"nctId":"NCT05787002","phase":"PHASE1","title":"A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"Dyslipidemia","enrollment":16},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT06924684","phase":"PHASE2","title":"High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2024-12-02","conditions":"ST Elevation (STEMI) Myocardial Infarction","enrollment":66},{"nctId":"NCT06105060","phase":"EARLY_PHASE1","title":"Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2023-12-17","conditions":"Non-alcoholic Steatohepatitis","enrollment":175},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT05895123","phase":"PHASE2","title":"Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2021-11-01","conditions":"ST-segment Elevation Myocardial Infarction","enrollment":80},{"nctId":"NCT05384262","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-18","conditions":"Dyslipidemia","enrollment":183},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT05395117","phase":"PHASE1","title":"A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-30","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT04826354","phase":"PHASE4","title":"Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2021-08-11","conditions":"Atheroscleroses, Coronary","enrollment":582},{"nctId":"NCT05884502","phase":"PHASE4","title":"A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dyslipidemias, Stroke, Acute Ischemic","enrollment":330},{"nctId":"NCT02841774","phase":"PHASE2","title":"High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV","status":"COMPLETED","sponsor":"Matthew Feinstein","startDate":"2016-11","conditions":"HIV Infection, Coronary Heart Disease","enrollment":10},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT05306990","phase":"NA","title":"Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Helwan University","startDate":"2017-04-20","conditions":"Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus","enrollment":108},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT00651144","phase":"PHASE1","title":"Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":40},{"nctId":"NCT01154036","phase":"PHASE3","title":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-07","conditions":"Hypercholesterolemia","enrollment":1547},{"nctId":"NCT02586155","phase":"PHASE3","title":"Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD","status":"COMPLETED","sponsor":"Resverlogix Corp","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":2425},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04923152","phase":"NA","title":"Effective Dose of Statin Post PCI","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2020-01-01","conditions":"Statin Dose","enrollment":582},{"nctId":"NCT03474562","phase":"PHASE4","title":"High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-04-03","conditions":"ASCVD, Impaired Fasting Glucose, Hypertension","enrollment":100},{"nctId":"NCT01382472","phase":"PHASE4","title":"Microcirculation In Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2011-09","conditions":"ST Elevation (STEMI) Myocardial Infarction","enrollment":25},{"nctId":"NCT02041117","phase":"PHASE4","title":"Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2014-02-24","conditions":"Intracranial Arterial Stenosis","enrollment":162},{"nctId":"NCT00966472","phase":"PHASE1","title":"Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2009-03","conditions":"Squamous Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT04080310","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-03-15","conditions":"Cardiovascular Diseases","enrollment":270},{"nctId":"NCT01420549","phase":"PHASE3","title":"Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-03","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":129},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04056169","phase":"PHASE4","title":"Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-06-29","conditions":"Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation","enrollment":50},{"nctId":"NCT03657758","phase":"PHASE4","title":"Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]","status":"UNKNOWN","sponsor":"Kobe University","startDate":"2018-09-17","conditions":"Coronary Artery Disease, Angina Pectoris","enrollment":75},{"nctId":"NCT03192579","phase":"PHASE4","title":"Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial","status":"COMPLETED","sponsor":"Kobe University","startDate":"2013-07-26","conditions":"Coronary Artery Disease Progression","enrollment":50},{"nctId":"NCT01350141","phase":"PHASE2","title":"A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":46},{"nctId":"NCT01342211","phase":"PHASE2","title":"A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":93},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT02458755","phase":"PHASE4","title":"Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-02","conditions":"Stroke, Intracranial Atherosclerosis","enrollment":80},{"nctId":"NCT01926782","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":803},{"nctId":"NCT03007524","phase":"PHASE4","title":"Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2016-07","conditions":"Acute Coronary Syndrome","enrollment":80},{"nctId":"NCT01870804","phase":"PHASE4","title":"Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)","status":"COMPLETED","sponsor":"Centro Cardiopatici Toscani","startDate":"2013-05","conditions":"Acute Coronary Syndrome","enrollment":760},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01617655","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-06","conditions":"Hypercholesterolaemia","enrollment":107},{"nctId":"NCT02859480","phase":"PHASE4","title":"Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2015-09","conditions":"Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases","enrollment":300},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT02305862","phase":"NA","title":"A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2013-01","conditions":"Arteriosclerosis, Diabetes Mellitus, Lipid Disorder","enrollment":150},{"nctId":"NCT02518516","phase":"","title":"High Potency Statins and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":2067639},{"nctId":"NCT02518503","phase":"","title":"High Potency Statins and the Risk of Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-07","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Disease","enrollment":136966},{"nctId":"NCT01507831","phase":"PHASE3","title":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Hypercholesterolemia","enrollment":2341},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT02593487","phase":"PHASE4","title":"Effect of Rosuvastatin Therapy on HDL2 Level","status":"UNKNOWN","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2015-11","conditions":"Hyperlipemia, Coronary Heart Disease","enrollment":300},{"nctId":"NCT01544309","phase":"NA","title":"LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts","status":"COMPLETED","sponsor":"Listen Trial Group","startDate":"2012-03","conditions":"Hypercholesterolemia With Concomitant Type 2 Diabetes","enrollment":1049},{"nctId":"NCT00997880","phase":"PHASE4","title":"Statin and Atheroma Vulnerability Evaluation","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2010-04","conditions":"Coronary Artery Disease","enrollment":312},{"nctId":"NCT02314286","phase":"PHASE1, PHASE2","title":"Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2014-12","conditions":"Severe Pre-eclampsia","enrollment":100},{"nctId":"NCT01929070","phase":"PHASE1","title":"A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2013-02","conditions":"Healthy","enrollment":12},{"nctId":"NCT01526460","phase":"PHASE2","title":"Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2011-08","conditions":"Platelet Dysfunction","enrollment":146},{"nctId":"NCT01971606","phase":"PHASE4","title":"Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2007-10","conditions":"A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.","enrollment":234},{"nctId":"NCT01899027","phase":"PHASE4","title":"Rosuvastatin for Preventing Complications in Renal Ablation","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2014-01","conditions":"Arterial Hypertension","enrollment":112},{"nctId":"NCT01228227","phase":"PHASE3","title":"ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading","status":"COMPLETED","sponsor":"Gennaro Sardella","startDate":"2010-10","conditions":"Assess the Periprocedural Myocardial Necrosis","enrollment":310},{"nctId":"NCT01653119","phase":"NA","title":"Peking and Rotterdam on Mission to Reduce Coronary Artery Disease","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2012-04","conditions":"Acute Coronary Syndrome, Diabetes Mellitus","enrollment":1000},{"nctId":"NCT00249899","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":649},{"nctId":"NCT00683618","phase":"PHASE3","title":"Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Hypercholesterolemia","enrollment":934},{"nctId":"NCT00526721","phase":"","title":"Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Hypercholesterolemia","enrollment":1482},{"nctId":"NCT00240344","phase":"","title":"Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Hypercholesterolemia","enrollment":2650},{"nctId":"NCT00347217","phase":"","title":"Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-02","conditions":"Hypercholesteremia","enrollment":3840},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT01245894","phase":"PHASE4","title":"Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2007-11","conditions":"Myocardial Infarction [C14.907.585.500]","enrollment":87},{"nctId":"NCT00240305","phase":"PHASE3","title":"A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-04","conditions":"Metabolic Syndrome, Dyslipidemia","enrollment":15},{"nctId":"NCT00654394","phase":"PHASE3","title":"Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2000-01","conditions":"Carotid Artery Stenosis, Hypercholesterolemia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rosuvastatin Calcium","Crestor"],"phase":"marketed","status":"active","brandName":"High dose Rosuvastatin","genericName":"High dose Rosuvastatin","companyName":"Nanjing First Hospital, Nanjing Medical University","companyId":"nanjing-first-hospital-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of LDL cholesterol in patients at high cardiovascular risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}